Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Novel Oncology Drugs in Clinical Development in NETHERLANDS

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Lava Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              NETHERLANDS Netherlands

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ISPE Manufacturing

              Participation Not Confirmed

              Update your events

              Lava Therapeutics Announces Collaboration with Janssen to Develop Bi-specific Gamma-Delta T-cell Engager Therapeutics

              Contact the Supplier

              Lead Product(s): V?9V?2 T cells based antibodies

              Therapeutic Area: Oncology

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Johnson & Johnson

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 15, 2020

              Details:

              Lava Therapeutics will perform discovery and product development activities, and is eligible to receive an undisclosed financial package consisting of an upfront payment and potential development and commercial milestones, and future tiered royalties.

              Kiadis Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              NETHERLANDS Netherlands

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ISPE Manufacturing

              Participation Not Confirmed

              Update your events

              Kiadis Pharma Files First Investigational New Drug Application with The U.S. FDA for Natural Killer Cell Therapy

              Contact the Supplier

              Lead Product(s): K-NK002

              Therapeutic Area: Oncology

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 09, 2020

              Details:

              IND supports the Company’s planned NK-REALM Phase 1/2 study which will evaluate K-NK002 in 63 patients with blood cancer undergoing a haploidentical hematopoietic stem cell transplant (HSCT).

              Lava Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              NETHERLANDS Netherlands

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ISPE Manufacturing

              Participation Not Confirmed

              Update your events

              ProBioGen, Lava Therapeutics Sign Cell Line Mfg. Pact

              Contact the Supplier

              Lead Product(s): Vγ9Vδ2 T cells based antibodies,V?9V?2 T cells based antibodies

              Therapeutic Area: Oncology

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: ProBioGen

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 14, 2020

              Details:

              Under the agreement and using its CHO.RiGHT™ expression platform, ProBioGen will conduct cell line development of a ?? T-cell engaging bispecific antibody format.

              Synaffix

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              NETHERLANDS Netherlands

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ISPE Manufacturing

              Participation Not Confirmed

              Update your events

              Synaffix announces expansion of license agreement with Shanghai Miracogen Inc. to a second ADC candidate

              Contact the Supplier

              Lead Product(s): Antibody drug conjugate linker

              Therapeutic Area: Oncology

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Shanghai Miracogen

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 07, 2020

              Details:

              Miracogen has been granted non-exclusive rights to Synaffix’s proprietary GlycoConnect™ and HydraSpace™ ADC technologies for use in this second clinical candidate.

              PharmaCompass__DigitalAd